Carisma Therapeutics, Inc. (CARM)

1,6400 0,0000 (0,00%) Alla chiusura: 04:00PM EDT

Carisma Therapeutics, Inc.

3675 Market Street
Suite 200
Philadelphia, PA 19104
United States
267-491-6422
https://www.carismatx.com

Settore/i: Healthcare
Settore: Biotechnology
Impiegati a tempo pieno: 107

Figure dirigenziali chiave

Nome	Titolo	Retribuzione	Esercitate	Anno di nascita
Mr. Steven Kelly	President, CEO & Director	666k	N/D	1965
Mr. Michael Klichinsky Ph.D., Pharm.D., PharmD	Co-Founder & Chief Scientific Officer	469k	N/D	1990
Mr. Richard S. Morris CPA	CFO, Chief Compliance Officer, Treasurer, Prin. Financial Off. & Prin. Acc. Off.	570k	N/D	1974
Dr. Saar Gill M.D., Ph.D.	Co-Founder & Chairman of Scientific Advisory Board	N/D	N/D	N/D
Dr. Daniel J. Cushing FCP, Ph.D.	Chief Technology & Development Officer	N/D	N/D	N/D
Mr. Eric H. Siegel J.D., MBA	General Counsel & Corporate Secretary	N/D	N/D	1965
Ms. Terry Shields	Senior Vice President of Human Resources	N/D	N/D	N/D
Mr. Tom Wilton	Chief Business Officer	N/D	N/D	1974

Gli importi risalgono al giorno 31 dicembre 2022 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in USD.

Descrizione

Carisma Therapeutics, Inc., a clinical-stage cell therapy company, focuses on discovering and developing immunotherapies to treat cancer and other serious diseases in the United States. The company's ex vivo CAR-M cell therapies include CT-0508, a CAR-macrophage, which is in Phase 1 clinical trial to treat solid tumors; CT-0525, a CAR-monocyte that is in Phase 1 clinical trial to treat solid tumors; and CT-1119, a mesothelin-targeted CAR-Monocyte that is in pre-clinical stage to treat patients with advanced mesothelin-positive solid tumors, including lung cancer, mesothelioma, pancreatic cancer, ovarian cancer, and others. It is also developing in vivo CAR-M cell therapies in collaboration with Moderna Therapeutics to address multiple cancer targets; and multiple assets for the potential treatment of diseases beyond oncology, including fibrosis and other immunologic and inflammatory diseases. The company was formerly known as CARMA Therapeutics Inc. and changed its name to Carisma Therapeutics, Inc. in May 2017. The company was founded in 2016 and is headquartered in Philadelphia, Pennsylvania.

Governance aziendale

L'ISS Governance QualityScore di Carisma Therapeutics, Inc. al 1 aprile 2024 è 7. I criteri di valutazione fondamentali sono revisione: 9; Consiglio di Amministrazione: 6; diritti degli azionisti: 7; retribuzione: 8.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.